◼ Archived
Business
🔮 fades ✓
MapLight shares sink on mixed ph. 2 schizophrenia readout
MapLight Therapeutics stock plummeted 73% following mixed phase 2 trial data for its schizophrenia candidate, ML-007C-MA.
Mplt
2 independently checked trend briefs about this subject, newest first.
What this Mplt timeline shows
headlinez.news detected 2 source-qualified news clusters connected to Mplt between July 27, 2026 and July 27, 2026. They span 1 newsroom category and average 5.5 independent sources per brief.
This hub includes only briefs supported by at least four sources and passed by the site's verification gate. Raw or weak detections may exist but are excluded here. Topic matching is based on the entities and themes recorded with each brief; open a card to inspect its source links, publication time, verification label and velocity history. Read the methodology and editorial policy for the full rules.
◼ Archived
Business
🔮 fades ✓
5 Things to Know Before the Stock Market Opens on Monday
A surprise lineup of biotech and tech stocks is set to dominate Monday’s market opening, forcing investors to rethink their early‑day playbook.